411 related articles for article (PubMed ID: 24778063)
1. Prevention of osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates.
DE Iuliis F; Taglieri L; Amoroso L; Vendittozzi S; Blasi L; Salerno G; Lanza R; Scarpa S
Anticancer Res; 2014 May; 34(5):2477-80. PubMed ID: 24778063
[TBL] [Abstract][Full Text] [Related]
2. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.
Bamias A; Kastritis E; Bamia C; Moulopoulos LA; Melakopoulos I; Bozas G; Koutsoukou V; Gika D; Anagnostopoulos A; Papadimitriou C; Terpos E; Dimopoulos MA
J Clin Oncol; 2005 Dec; 23(34):8580-7. PubMed ID: 16314620
[TBL] [Abstract][Full Text] [Related]
3. Osteonecrosis of the jaw as an adverse bisphosphonate event: three cases of bone metastatic prostate cancer patients treated with zoledronic acid.
García Sáenz JA; López Tarruella S; García Paredes B; Rodríguez Lajusticia L; Villalobos L; Díaz Rubio E
Med Oral Patol Oral Cir Bucal; 2007 Sep; 12(5):E351-6. PubMed ID: 17767097
[TBL] [Abstract][Full Text] [Related]
4. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate.
Walter C; Al-Nawas B; Grötz KA; Thomas C; Thüroff JW; Zinser V; Gamm H; Beck J; Wagner W
Eur Urol; 2008 Nov; 54(5):1066-72. PubMed ID: 18602738
[TBL] [Abstract][Full Text] [Related]
5. Osteonecrosis of the Jaw in Patients Receiving Bone-Targeted Therapies: An Overview--Part I.
Turner B; Drudge-Coates L; Ali S; Pati J; Nargund V; Ali E; Cheng L; Wells P
Urol Nurs; 2016; 36(3):111-6, 154. PubMed ID: 27501591
[TBL] [Abstract][Full Text] [Related]
6. Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab.
Loyson T; Van Cann T; Schöffski P; Clement PM; Bechter O; Spriet I; Coropciuc R; Politis C; Vandeweyer RO; Schoenaers J; Dumez H; Berteloot P; Neven P; Nackaerts K; Woei-A-Jin FJSH; Punie K; Wildiers H; Beuselinck B
Acta Clin Belg; 2018 Apr; 73(2):100-109. PubMed ID: 28693379
[TBL] [Abstract][Full Text] [Related]
7. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
[TBL] [Abstract][Full Text] [Related]
8. Osteonecrosis of the jaw in prostate cancer patients with bone metastases treated with zoledronate: a retrospective analysis.
Ortega C; Montemurro F; Faggiuolo R; Vormola R; Nanni D; Goia F; Gilardino MO; Aglietta M
Acta Oncol; 2007; 46(5):664-8. PubMed ID: 17562443
[TBL] [Abstract][Full Text] [Related]
9. A 5-year retrospective longitudinal study on the incidence and the risk factors of osteonecrosis of the jaws in patients treated with zoledronic acid for bone metastases from solid tumors.
Manfredi M; Mergoni G; Goldoni M; Salvagni S; Merigo E; Meleti M; Vescovi P
Med Oral Patol Oral Cir Bucal; 2017 May; 22(3):e342-e348. PubMed ID: 28390132
[TBL] [Abstract][Full Text] [Related]
10. Osteonecrosis of the jaw: dental outcomes in metastatic breast cancer patients treated with bisphosphonates with/without bevacizumab.
Ngamphaiboon N; Frustino JL; Kossoff EB; Sullivan MA; O'Connor TL
Clin Breast Cancer; 2011 Aug; 11(4):252-7. PubMed ID: 21729657
[TBL] [Abstract][Full Text] [Related]
11. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan.
Ripamonti CI; Maniezzo M; Campa T; Fagnoni E; Brunelli C; Saibene G; Bareggi C; Ascani L; Cislaghi E
Ann Oncol; 2009 Jan; 20(1):137-45. PubMed ID: 18647964
[TBL] [Abstract][Full Text] [Related]
12. Osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates: a retrospective study.
Ibrahim T; Barbanti F; Giorgio-Marrano G; Mercatali L; Ronconi S; Vicini C; Amadori D
Oncologist; 2008 Mar; 13(3):330-6. PubMed ID: 18378544
[TBL] [Abstract][Full Text] [Related]
13. Osteonecrosis of the jaws associated with the use of yearly zoledronic acid: report of 2 cases.
Lee JJ; Cheng SJ; Wang YP; Jeng JH; Chiang CP; Kok SH
Head Neck; 2013 Jan; 35(1):E6-10. PubMed ID: 21523843
[TBL] [Abstract][Full Text] [Related]
14. Impact of dental care in the prevention of bisphosphonate-associated osteonecrosis of the jaw: a single-center clinical experience.
Vandone AM; Donadio M; Mozzati M; Ardine M; Polimeni MA; Beatrice S; Ciuffreda L; Scoletta M
Ann Oncol; 2012 Jan; 23(1):193-200. PubMed ID: 21427065
[TBL] [Abstract][Full Text] [Related]
15. Bisphosphonate-induced osteonecrosis of the jaw (ONJ): Incidence and risk factors in patients with breast cancer and gynecological malignancies.
Fehm T; Beck V; Banys M; Lipp HP; Hairass M; Reinert S; Solomayer EF; Wallwiener D; Krimmel M
Gynecol Oncol; 2009 Mar; 112(3):605-9. PubMed ID: 19136147
[TBL] [Abstract][Full Text] [Related]
16. Surgical treatment of bisphosphonate-associated osteonecrosis of the jaw: technical report and follow up of 21 patients.
Voss PJ; Joshi Oshero J; Kovalova-Müller A; Veigel Merino EA; Sauerbier S; Al-Jamali J; Lemound J; Metzger MC; Schmelzeisen R
J Craniomaxillofac Surg; 2012 Dec; 40(8):719-25. PubMed ID: 22336489
[TBL] [Abstract][Full Text] [Related]
17. Preventive Strategies for Patients at Risk of Medication-related Osteonecrosis of the Jaw.
Goodday RH
Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):527-36. PubMed ID: 26293331
[TBL] [Abstract][Full Text] [Related]
18. Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy.
Estilo CL; Van Poznak CH; Wiliams T; Bohle GC; Lwin PT; Zhou Q; Riedel ER; Carlson DL; Schoder H; Farooki A; Fornier M; Halpern JL; Tunick SJ; Huryn JM
Oncologist; 2008 Aug; 13(8):911-20. PubMed ID: 18695259
[TBL] [Abstract][Full Text] [Related]
19. Pentoxifylline and tocopherol in the treatment of yearly zoledronic acid-related osteonecrosis of the jaw in a corticosteroid-induced osteoporosis.
Magremanne M; Reychler H
J Oral Maxillofac Surg; 2014 Feb; 72(2):334-7. PubMed ID: 23891014
[TBL] [Abstract][Full Text] [Related]
20. Bisphosphonate-associated osteonecrosis: a clinician's reference to patient management.
Grewal VS; Fayans EP
Todays FDA; 2008 Aug; 20(8):38-41, 43-6. PubMed ID: 18767452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
